Life Sciences Archives - Page 10 of 17 - Becker's Hospital Review

Mark Cuban dives into drug manufacturing | Drugmakers send CMS counteroffers in fair price negotiations | 8 Ozempic updates | 1st OTC glucose monitor cleared | FDA revokes approval of Pepaxto

March 6, 2024 BHR Newsletter 1. Mark Cuban's pharma company to start manufacturing 2 drugs this week Full story 2. HHS intervenes in Change Healthcare hack Full story 3. 8 Ozempic updates Full story 4. Behind a big chunk of…

Weight loss drug candidate could rival Ozempic | State board sets a drug price ceiling | NY asks FDA to address Singulair controversy | Amgen builds $474M facility | 2 drugs nearing approval to know

February 28, 2024 BHR Newsletter 1. A weight loss drug candidate could rival Ozempic Full story 2. Justice Department begins antitrust investigation into UnitedHealth Full story 3. For 1st time, state board sets a drug price ceiling Full story 4.…

Drugmakers struggle to gain traction for gene therapies | AbbVie CEO to step down | FDA places clinical holds on 2 drug studies | 1st T cell melanoma drug approved | 10 drugs now in shortage

February 21, 2024 BHR Newsletter 1. Buzz for gene therapies is loud, but drugmakers struggle to get treatments off the ground Full story 2. The tide is turning on healthcare megamergers Full story 3. 10 drugs now in shortage Full…

Gilead scoops drugmaker for $4.3B | 6 Ozempic updates | UT Southwestern, Pfizer partner | 55 best hospitals to work for: Forbes | FDA clears metastatic pancreatic cancer drug

February 14, 2024 BHR Newsletter 1. Gilead scoops drugmaker for $4.3B Full story 2. Best large, midsize health system employers: Forbes Full story 3. 6 Ozempic updates Full story 4. MedStar overhauled its scheduling strategy for better efficiency + provider…

Biogen pulls Aduhelm | Amazon cuts healthcare jobs | 2 cancer drug injectables go into shortage | 5 Ozempic updates | 6 cancer vaccines showing promise

February 7, 2024 BHR Newsletter 1. Biogen abandons controversial Alzheimer's drug Aduhelm Full story 2. Amazon cuts jobs in healthcare divisions Full story 3. 2 more cancer drug injectables fall into shortage Full story 4. Hospitals ahead of the staffing…

Paxlovid emergency use to end | Drugmakers look to class of cancer drugs for growth | Contaminated medical products tied to cases of early Alzheimer's | Gene therapy allows boy to hear | 9 drugs now in shortage

January 31, 2024 BHR Newsletter 1. FDA sets end date for Paxlovid emergency use Full story 2. Contaminated medical products tied to cases of early Alzheimer's Full story 3. Drugmakers turn to class of cancer drugs to fuel growth in…

FDA finds deficiencies at Eli Lilly plant | Ozempic, Mounjaro get pricier | Drug cost trends in 2024 are 'nearly unprecedented' | Best, worst states to retire | FDA clears CRISPR therapy for 2nd disease

January 24, 2024 BHR Newsletter 1. FDA finds deficiencies at Eli Lilly plant: Reuters Full story 2. The best, worst states to retire Full story 3. Ozempic, Mounjaro become pricier Full story 4. The call center is going out of…

Drugmaker halts study after 2 unrelated deaths | Developing a staph vaccine when 'the rules are different' | Eli Lilly weight-loss drug platform draws concern | 5 new drug shortages

January 17, 2024 BHR Newsletter 1. How to develop a staph vaccine when 'the rules are different' Full story 2. New cancer diagnoses set to hit a new high in 2024: American Cancer Society Full story 3. Drugmaker halts study…

J&J to buy Ambrx for $2B | Eli Lilly to sell weight loss drugs directly to consumers | Pfizer to lay off 285 in NY | Best healthcare jobs in 2024 | 4 Ozempic updates

January 10, 2024 BHR Newsletter 1. Johnson & Johnson to buy Ambrx in $2B deal Full story 2. Best healthcare jobs in 2024: US News Full story 3. Eli Lilly to sell weight loss drugs directly to consumers; warns against…

Goldman Sachs closes on $650M life sciences investment fund | Bristol Myers to buy cancer therapy co. for $4B | FDA warns of infection risk over fake Ozempic | Verily's CMO steps down

January 3, 2024 BHR Newsletter 1. Goldman Sachs closes $650M healthcare investment fund to target life sciences Full story 2. Michael Dowling: The most pressing question to start the year Full story 3. Bristol Myers to buy cancer therapy company…